He Qinghua, head of the National Health Commission’s Bureau of Disease Control. Photograph Cover News Reporter Dai Rui Cover News Reporter Dai Rui On February 11, the State Council Information Office held a conference on effectively strengthening the scientific prevention and control of the epidemic, and orderly doing a good job in the resumption of work and production by enterprises. After the conference, the national health commission disease control bureau first-class inspector He Qinghua told the cover news reporter, at present the antiviral drug Ridaxivir clinical trial results have not yet come out, the specific time of the results “is not clear”. Previously, the antiviral drug Raltegravir caused concern. Xinhua News Agency reported that on the evening of February 6, the antiviral drug Ridecivir clinical trials have been launched in Wuhan Jingyintan Hospital. According to Xinhua News Agency report, Ridecivir clinical trial project leader, vice president of China-Japan Friendship Hospital, Prof. Cao Bin introduced, Ridecivir is the U.S. Gilead’s drug in development, in the preliminary cell and animal experiments have shown better antiviral activity against SARS coronavirus, MERS coronavirus, foreign countries have carried out Ridecivir against Ebola coronavirus infection clinical trials; recently, China’s Recently, scholars reported that raltegravir also has better activity against 2019 new coronavirus at the cellular level, but rigorous clinical trials are still needed to evaluate it before human application. Currently there is a lack of effective antiviral drugs for patients with novel coronavirus infections, and we look forward to the performance of raltegravir in the clinic. Source: Cover News